J&J unit wants rights to Remicade back from Schering-Plough

Johnson & Johnson subsidiary Centocor said it warned Schering-Plough of its plans to seek arbitration to regain full marketing rights to arthritis drug Remicade. The move comes as Merck & Co. works to take over Schering-Plough for $41.1 billion.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
White Plains, NY
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ